AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.
Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...
However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...
Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...
The added benefit is that AbbVie is a "Dividend King," which means it has consistently paid and increased dividends for ...
As most advisors are well aware, high stock prices have pushed down the market’s dividend yield. Barron’s ran a screen for ...
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
AbbVie (NYSE:ABBV) has once again raised its full-year outlook on soaring demand for its newer immunology medicines, Skyrizi ...
AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct. 15th. While investors will wait to hear about quarterly earnings on ...
AbbVie (NYSE: ABBV) continues to demonstrate its prowess in navigating the challenging landscape of drug development and ...